RT Journal Article
SR Electronic
A1 Jacobson, Anne
T1 ONTARGET: Treatment Nonadherence Rapidly Increases CV Event Risk
JF MD Conference Express
YR 2011
FD SAGE Publications
VO 11
IS 10
SP 26
OP 26
DO 10.1177/155989771110017
UL http://mdc.sagepub.com/content/11/10/26.abstract
AB Patients who are at high risk for cardiovascular events face a vicious cycle in which treatment nonadherence increases event rates while events themselves reinforce nonadherence, according to new findings from the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET].